<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sequana Medical N.v — News on 6ix</title>
<link>https://6ix.com/company/sequana-medical-nv-1</link>
<description>Latest news and press releases for Sequana Medical N.v on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 29 May 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sequana-medical-nv-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68f4fbeedb30cb6fefdfd.webp</url>
<title>Sequana Medical N.v</title>
<link>https://6ix.com/company/sequana-medical-nv-1</link>
</image>
<item>
<title>Sequana Medical Announces Presentation on Recompensation of Decompensated Cirrhosis Following alfapump® Placement at EASL Congress 2026</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-presentation-on-recompensation-of-decompensated-cirrhosis-following-alfapumpr-placement-at-easl-congress-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-presentation-on-recompensation-of-decompensated-cirrhosis-following-alfapumpr-placement-at-easl-congress-2026</guid>
<pubDate>Fri, 29 May 2026 05:00:00 GMT</pubDate>
<description>Ghent, Belgium, May 29, 2026 (GLOBE NEWSWIRE) -- Post-hoc analysis from the POSEIDON study demonstrates long-term resolution of ascites and early signs of liver function recovery in over 20% of patients with alfapump in situ for over six monthsThis important finding builds upon the virtual elimination of therapeutic paracentesis and an improvement in quality of life in the POSEIDON study previously reported1 Ghent, Belgium, 29 May 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company</description>
</item>
<item>
<title>Sequana Medical announces results of Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-results-of-annual-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-results-of-annual-general-meeting-of-shareholders</guid>
<pubDate>Thu, 28 May 2026 19:00:00 GMT</pubDate>
<description>Ghent, Belgium, May 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION | 28 May 2026, 9:00 pm CEST Ghent, Belgium – 28 May 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today the results of the Annual General Meeting of Shareholders (the "AGM") held today at 09:00 am CEST, at which the treatment of certain agenda items was</description>
</item>
<item>
<title>Financial and Strategic Review, Annual General Meeting, and Trading Halt</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/financial-and-strategic-review-annual-general-meeting-and-trading-halt-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/financial-and-strategic-review-annual-general-meeting-and-trading-halt-1</guid>
<pubDate>Tue, 28 Apr 2026 20:00:00 GMT</pubDate>
<description>Ghent, Belgium, April 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION - INSIDE INFORMATION28 April 2026, 10:00 pm CEST Ghent, Belgium, 28 April 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that it is conducting a review of a range of financial and strategic options to address its current financial position and the</description>
</item>
<item>
<title>NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES / ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/new-share-capital-amount-and-new-number-of-shares-issuance-of-a-new-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-2</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/new-share-capital-amount-and-new-number-of-shares-issuance-of-a-new-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-2</guid>
<pubDate>Thu, 26 Mar 2026 19:00:00 GMT</pubDate>
<description>Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS ("GEM"), the Company's share capital has increased o</description>
</item>
<item>
<title>Sequana Medical Reports Strong US Commercial Progress with Five Centers Completing alfapump® System Implants Since Launch</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-reports-strong-us-commercial-progress-with-five-centers-completing-alfapumpr-system-implants-since-launch</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-reports-strong-us-commercial-progress-with-five-centers-completing-alfapumpr-system-implants-since-launch</guid>
<pubDate>Thu, 26 Feb 2026 06:00:00 GMT</pubDate>
<description>Ghent, Belgium, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Leading US liver transplant center completes its first two implantationsMount Sinai Hospital and University of Pennsylvania also complete multiple implantations Dartmouth Hitchcock Medical Center and University Medical Center of Southern Nevada each conduct first implantation Ghent, Belgium, 26 February 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid over</description>
</item>
<item>
<title>SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-the-issuance-of-a-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-the-issuance-of-a-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</guid>
<pubDate>Mon, 02 Feb 2026 17:00:00 GMT</pubDate>
<description>Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION2 February 2026, 6:00 pm CET Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Fac</description>
</item>
<item>
<title>SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-new-share-capital-amount-and-new-number-of-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-new-share-capital-amount-and-new-number-of-shares-1</guid>
<pubDate>Tue, 27 Jan 2026 06:00:00 GMT</pubDate>
<description>Ghent, Belgium, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES PRESS RELEASEREGULATED INFORMATION 27 January 2026, 7:00 am CET Ghent, Belgium, 27 January 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LL</description>
</item>
<item>
<title>Transparency Notification from Shareholders</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/transparency-notification-from-shareholders-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/transparency-notification-from-shareholders-1</guid>
<pubDate>Tue, 06 Jan 2026 17:00:00 GMT</pubDate>
<description>Ghent, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transparency Notification from ShareholdersPRESS RELEASEREGULATED INFORMATION 6 January 2026, 6:00 pm CET Ghent, Belgium – 6 January 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the numbe</description>
</item>
<item>
<title>Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-execution-of-letter-of-intent-to-amend-terms-of-the-kreos-loan-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-execution-of-letter-of-intent-to-amend-terms-of-the-kreos-loan-1</guid>
<pubDate>Tue, 23 Dec 2025 17:30:00 GMT</pubDate>
<description>Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan PRESS RELEASE REGULATED INFORMATION / INSIDE INFORMATION23 December 2025, 6:30 pm CET / 12:30 pm ET Letter of intent to amend the loan from funds managed by Kreos, including an extension of the interest only period and deferral of amortization paymentsAdditional runway supports ongoing alfapump commercial rollout in the U.S. Ghent, Belgium – 23 December 2025</description>
</item>
<item>
<title>Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-granting-of-key-additional-us-patent-for-dsr-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-granting-of-key-additional-us-patent-for-dsr-1</guid>
<pubDate>Thu, 18 Dec 2025 06:00:00 GMT</pubDate>
<description>Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and ChinaStrengthens DSR patent protection based upon extensive clinical and pre-clinical experienceData published in European Journal of Heart Failure supports DSR as breakthrough in treatment of cardiorenal syndrome and diuretic-resistant heart failureUS MOJAVE clinical study of DSR vs IV loop diuretics planned to enter randomized controlled phase following dedicated DSR financing Se</description>
</item>
<item>
<title>Sequana Medical Announces U.S. Commercial alfapump® Implantations at University of Pennsylvania</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-us-commercial-alfapumpr-implantations-at-university-of-pennsylvania-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-us-commercial-alfapumpr-implantations-at-university-of-pennsylvania-1</guid>
<pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
<description>Ghent, Belgium, Dec. 11, 2025 (GLOBE NEWSWIRE) -- First implantation of two alfapump patients on the same dayContinuing strategy of working with Key Opinion Leaders at top tier centersStrong pipeline of additional implanting centers supports commercial momentumOngoing progress in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosis Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the trea</description>
</item>
<item>
<title>Press release: Transparency Notification from Shareholders</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-transparency-notification-from-shareholders-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-transparency-notification-from-shareholders-1</guid>
<pubDate>Mon, 24 Nov 2025 17:30:00 GMT</pubDate>
<description>Ghent, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders Ghent, Belgium – 24 November 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their nam</description>
</item>
<item>
<title>Sequana Medical Announces First U.S. Commercial alfapump® Implantation at Mount Sinai Hospital in New York</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-first-us-commercial-alfapumpr-implantation-at-mount-sinai-hospital-in-new-york-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-announces-first-us-commercial-alfapumpr-implantation-at-mount-sinai-hospital-in-new-york-1</guid>
<pubDate>Mon, 24 Nov 2025 06:00:00 GMT</pubDate>
<description>Ghent, Belgium, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Milestone in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosisFeedback from hepatology community supports US market potential from this large and growing market driven by obesityKey step in validation of Sequana Medical’s strategy of targeting US transplant centers through its specialty commercial teamContinued strong progress in US commercial roll-out Sequana Medical NV (Euronext B</description>
</item>
<item>
<title>Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-new-share-capital-amount-and-new-number-of-shares-issuance-of-a-new-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-new-share-capital-amount-and-new-number-of-shares-issuance-of-a-new-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</guid>
<pubDate>Thu, 16 Oct 2025 16:00:00 GMT</pubDate>
<description>Ghent, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 16 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yiel</description>
</item>
<item>
<title>Sequana Medical alfapump® System Highlighted at SIR EDGE 2025 Conference</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-alfapumpr-system-highlighted-at-sir-edge-2025-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/sequana-medical-alfapumpr-system-highlighted-at-sir-edge-2025-conference-1</guid>
<pubDate>Tue, 14 Oct 2025 16:00:00 GMT</pubDate>
<description>Ghent, Belgium, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA (the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that the alfapump System was highlighted in a presentation at the Society of Interventional Radiology’s SIR EDGE 2025 conference in San Diego. The presentation titled “Not the Alpha Male, the Alfapump!” showcased the clinical impact and innovative</description>
</item>
<item>
<title>Press release: Transparency Notification from Shareholder</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-transparency-notification-from-shareholder-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-transparency-notification-from-shareholder-1</guid>
<pubDate>Mon, 13 Oct 2025 16:00:00 GMT</pubDate>
<description>Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entity listed below, notifying the number of voting rights attached to the shares mentioned next to its name in the table below. Reason for notificationAg</description>
</item>
<item>
<title>Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-sequana-medical-announces-new-share-capital-amount-and-new-number-of-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-sequana-medical-announces-new-share-capital-amount-and-new-number-of-shares-1</guid>
<pubDate>Fri, 26 Sep 2025 16:00:00 GMT</pubDate>
<description>SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 26 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today a capital increase in the framework of (i) a contribution in kind of certain convertible receivables (for an aggregate amount of EUR 214,000.00) due under the convertible loan agreemen</description>
</item>
<item>
<title>Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-sequana-medical-announces-the-issuance-of-a-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-sequana-medical-announces-the-issuance-of-a-subscription-request-notice-under-the-share-subscription-facility-agreement-with-gem-1</guid>
<pubDate>Mon, 15 Sep 2025 16:00:00 GMT</pubDate>
<description>SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 15 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Facili</description>
</item>
<item>
<title>Press release: CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-cms-approves-additional-payment-for-sequana-medicals-alfapumpr-system-in-hospital-inpatient-cases-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-cms-approves-additional-payment-for-sequana-medicals-alfapumpr-system-in-hospital-inpatient-cases-1</guid>
<pubDate>Tue, 05 Aug 2025 16:00:00 GMT</pubDate>
<description>CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases alfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in effect by October 1, 2025NTAP provides for up to $21,450 when performed in the hospital inpatient settingalfapump® US commercial launch remains on track for Q3 2025 through specialty commercial team focused on liver transplant centers Ghent, Belgium – 5 August 2025 – Sequana Medical NV (Euronext Brusse</description>
</item>
<item>
<title>Press release: Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia</title>
<link>https://6ix.com/company/sequana-medical-nv-1/news/press-release-use-of-alfapumpr-to-control-ascites-enabling-elective-umbilical-hernia-repair-published-in-hernia-1</link>
<guid isPermaLink="true">https://6ix.com/company/sequana-medical-nv-1/news/press-release-use-of-alfapumpr-to-control-ascites-enabling-elective-umbilical-hernia-repair-published-in-hernia-1</guid>
<pubDate>Thu, 31 Jul 2025 16:00:00 GMT</pubDate>
<description>Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a significant risk of complications that are life threatening and require emergency surgeryEffective management of ascites is necessary for elective surgical repair in such patientsThe team at Mayo Clinic, Arizona present a case report of a patient in the POSEIDON study that underwen</description>
</item>
</channel>
</rss>